{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/headache-cluster/","result":{"data":{"firstChapter":{"id":"dded59b4-b26d-58ac-b4b5-22a36bbce96f","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field dafcdb8d-c380-4639-a9ea-53c08bc23062 --><h1>Headache - cluster: Summary</h1><!-- end field dafcdb8d-c380-4639-a9ea-53c08bc23062 -->","htmlStringContent":"<!-- begin item 117ed6fd-7888-4a5e-9eb1-83960087c96c --><!-- begin field 35ded968-67b5-4f47-acd3-ba081fb75fdf --><ul><li>Cluster headache is a rare but severe primary headache disorder — it is the most common trigeminal autonomic cephalalgia.</li><li>It is characterized by:<ul><li>Recurrent attacks of one-sided pain, in or around the eye or temporal region.</li><li>Ipsilateral autonomic symptoms such as conjunctival injection and/or lacrimation, nasal congestion and/or rhinorrhoea, eyelid oedema, forehead and facial sweating or flushing.</li><li>Brief attacks of less than 3 hours duration.</li></ul></li><li>Cluster headache can be:<ul><li>Episodic with attacks occurring in periods lasting from 7 days to 1 year and separated by pain-free periods lasting at least 1 month.</li><li>Chronic with attacks occurring for more than 1 year without remission, or with remission periods lasting less than 1 month.</li></ul></li><li>The cause of cluster headache is not fully understood — in some people there may be an interaction between genetic and environmental factors.</li><li>During assessment of a person with suspected cluster headache clinicians should be alert for clinical features which may indicate a serious secondary cause of headache. </li><li>Referral to or discussion with a specialist (with urgency depending on the clinical situation) is recommended for people who:<ul><li>Have clinical features suggestive of a serious secondary cause of headache or where diagnosis is uncertain.</li><li>Present with a suspected first bout of cluster headache.</li><li>Are pregnant or breastfeeding.</li><li>Do not respond to management in primary care.</li></ul></li><li>Management of an acute attack of confirmed cluster headache in primary care involves:<ul><li>Offering a subcutaneous or nasal triptan (such as sumatriptan by subcutaneous injection) to people aged over 18 years (if appropriate).</li><li>Avoiding paracetamol, nonsteroidal anti-inflammatories, opioids, ergots and oral triptans.</li><li>Offering short burst oxygen therapy (100% oxygen at a flow rate of 12–15 litres per minute via a non-rebreather face mask for 15 to 20 minutes), if not contra-indicated.</li><li>Advising the person on avoidance of triggers.</li><li>Advising the person on the risk of medication overuse headache.</li><li>Identifying and managing any comorbidities such as depression, anxiety, and sleep apnoea.</li><li>Provision of written and oral patient information on cluster headache and support organizations.</li><li>Referral to a specialist if uncertain about diagnosis/management or first line measures in primary care fail.</li></ul></li></ul><!-- end field 35ded968-67b5-4f47-acd3-ba081fb75fdf --><!-- end item 117ed6fd-7888-4a5e-9eb1-83960087c96c -->","topic":{"id":"d4372db3-c286-5b08-ae88-4b378cc26f85","topicId":"1780a283-d8d8-4a78-9869-4aa0bcb926e5","topicName":"Headache - cluster","slug":"headache-cluster","aliases":[],"chapters":[{"id":"dded59b4-b26d-58ac-b4b5-22a36bbce96f","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"fb41d21e-afee-5c8f-9fe3-7e5d7273f990","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f42da194-bfee-5d0c-9cd9-fe2352e484d8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"603364e1-1e74-5796-9f29-7f6f277d42f3","slug":"changes","fullItemName":"Changes"},{"id":"49b37f22-5d81-55cd-9f09-2c42bfe7a440","slug":"update","fullItemName":"Update"}]},{"id":"fb7884e6-910a-5be8-b49b-4d0d9901e5bb","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"e4d8ae70-7df4-595f-b078-15b0686480bc","slug":"goals","fullItemName":"Goals"},{"id":"e06fcd82-7749-5fc4-99a5-a659ad138d75","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b2ce29d8-0327-5dc3-b537-4eb0d84ff0df","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"911f8cac-31a2-54f6-8084-565c4516e965","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"45526ba7-7e5c-5e4d-aea2-c6c4785109c9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"204fce42-b598-5c01-b2f8-dc34334f94ef","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d652875d-acbb-5f7e-9327-464a8d24509d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2513432e-c9c8-5a4a-b045-88b3c9db1c5f","slug":"definition","fullItemName":"Definition"},{"id":"f6b0ddc0-0058-5caa-a90e-fde4e7016138","slug":"cause","fullItemName":"Cause"},{"id":"24bb1ef8-f348-5f38-9375-b0ffcc04fe19","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad96cb6b-adfd-5eef-ac92-e130eebc9a8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"09b005ad-76ed-5ffb-9cf8-f7f5fdc3d524","slug":"complications","fullItemName":"Complications"}]},{"id":"eb2c501e-d43f-5455-b294-8c75e0b43b4f","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"99fb5731-772f-5d15-92ac-3e0d36235be9","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"dd1bbca4-1759-5853-a0b4-d6c95f1b4e22","slug":"assessment","fullItemName":"Assessment"},{"id":"270554de-33be-56a1-9ab5-db4bc1d5bfeb","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4952c884-725e-51f7-bde4-95e2418f6d18","slug":"management","fullItemName":"Management","subChapters":[{"id":"d58dee4b-524d-5c05-ab56-a3f2e8267015","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5dbc1f0e-638e-542a-bfb4-76477f824f0b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"bbfa7c46-4e1f-5d21-a8cb-de6d17b9dd04","slug":"sumatriptan-zolmitriptan","fullItemName":"Sumatriptan and zolmitriptan"}]},{"id":"49f18d8e-055b-5a9d-8737-d359c87ff9ae","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ae4fda2b-dde5-5641-aa58-5c38a3417e57","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1278ee56-1831-5a74-b634-e5de752cb567","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"11a5b228-ed75-5a88-aaef-1055082e8cfe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"88f71638-0d83-5cc8-9189-6a8cb83aede0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"04c06162-a368-59ad-b092-c583527f05a3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e2804080-7722-535f-84d1-3394e9874c9a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8b309d7e-58c0-5822-90e8-eb5941b856db","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"d4372db3-c286-5b08-ae88-4b378cc26f85","topicId":"1780a283-d8d8-4a78-9869-4aa0bcb926e5","topicName":"Headache - cluster","slug":"headache-cluster","aliases":[],"topicSummary":"Cluster headache is a rare but severe primary headache disorder  it is the most common trigeminal autonomic cephalalgia.","lastRevised":"Last revised in November 2017","nextPlannedReviewBy":"2022-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-11","nextPlannedReviewByDisplay":"November 2022","specialities":[{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"dded59b4-b26d-58ac-b4b5-22a36bbce96f","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"fb41d21e-afee-5c8f-9fe3-7e5d7273f990","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f42da194-bfee-5d0c-9cd9-fe2352e484d8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"603364e1-1e74-5796-9f29-7f6f277d42f3","slug":"changes","fullItemName":"Changes"},{"id":"49b37f22-5d81-55cd-9f09-2c42bfe7a440","slug":"update","fullItemName":"Update"}]},{"id":"fb7884e6-910a-5be8-b49b-4d0d9901e5bb","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"e4d8ae70-7df4-595f-b078-15b0686480bc","slug":"goals","fullItemName":"Goals"},{"id":"e06fcd82-7749-5fc4-99a5-a659ad138d75","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b2ce29d8-0327-5dc3-b537-4eb0d84ff0df","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"911f8cac-31a2-54f6-8084-565c4516e965","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"45526ba7-7e5c-5e4d-aea2-c6c4785109c9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"204fce42-b598-5c01-b2f8-dc34334f94ef","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d652875d-acbb-5f7e-9327-464a8d24509d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"2513432e-c9c8-5a4a-b045-88b3c9db1c5f","slug":"definition","fullItemName":"Definition"},{"id":"f6b0ddc0-0058-5caa-a90e-fde4e7016138","slug":"cause","fullItemName":"Cause"},{"id":"24bb1ef8-f348-5f38-9375-b0ffcc04fe19","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ad96cb6b-adfd-5eef-ac92-e130eebc9a8d","slug":"prognosis","fullItemName":"Prognosis"},{"id":"09b005ad-76ed-5ffb-9cf8-f7f5fdc3d524","slug":"complications","fullItemName":"Complications"}]},{"id":"eb2c501e-d43f-5455-b294-8c75e0b43b4f","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"99fb5731-772f-5d15-92ac-3e0d36235be9","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"dd1bbca4-1759-5853-a0b4-d6c95f1b4e22","slug":"assessment","fullItemName":"Assessment"},{"id":"270554de-33be-56a1-9ab5-db4bc1d5bfeb","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4952c884-725e-51f7-bde4-95e2418f6d18","slug":"management","fullItemName":"Management","subChapters":[{"id":"d58dee4b-524d-5c05-ab56-a3f2e8267015","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"5dbc1f0e-638e-542a-bfb4-76477f824f0b","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"bbfa7c46-4e1f-5d21-a8cb-de6d17b9dd04","slug":"sumatriptan-zolmitriptan","fullItemName":"Sumatriptan and zolmitriptan"}]},{"id":"49f18d8e-055b-5a9d-8737-d359c87ff9ae","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"ae4fda2b-dde5-5641-aa58-5c38a3417e57","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"1278ee56-1831-5a74-b634-e5de752cb567","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"11a5b228-ed75-5a88-aaef-1055082e8cfe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"88f71638-0d83-5cc8-9189-6a8cb83aede0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"04c06162-a368-59ad-b092-c583527f05a3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e2804080-7722-535f-84d1-3394e9874c9a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8b309d7e-58c0-5822-90e8-eb5941b856db","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"d4372db3-c286-5b08-ae88-4b378cc26f85"}},"staticQueryHashes":["3666801979"]}